What Are The Projected Market Size And CAGR For The Hemato Oncology Testing Market By The Conclusion Of 2030?
The hemato oncology testing market size has grown rapidly in recent years. It will grow from $3.93 billion in 2025 to $4.5 billion in 2026 at a compound annual growth rate (CAGR) of 14.4%. The growth in the historic period can be attributed to rising incidence of blood cancers, expansion of hospital diagnostic laboratories, increasing awareness of early cancer detection, growth in clinical research activities, availability of advanced testing reagents.
The hemato oncology testing market size is expected to see rapid growth in the next few years. It will grow to $7.76 billion in 2030 at a compound annual growth rate (CAGR) of 14.6%. The growth in the forecast period can be attributed to increasing adoption of precision oncology diagnostics, rising investments in genomic testing infrastructure, expansion of AI-driven diagnostic platforms, growing demand for companion diagnostics, continuous innovation in assay technologies. Major trends in the forecast period include increasing adoption of molecular diagnostic testing, rising use of next-generation sequencing in oncology, growing demand for personalized cancer diagnostics, expansion of automated laboratory testing platforms, enhanced integration of data analytics in hemato-oncology.
Claim Your Free Report Sample Today:
Which Drivers Are Expected To Support The Future Advancement Of The Hemato Oncology Testing Market?
The increasing incidence of hematologic cancer is expected to drive the growth of the hemato oncology testing market going forward. Hematologic cancer refers to a group of cancers that originate in the blood and affect the blood, bone marrow, and lymphatic system and include diseases such as leukemia, lymphoma, and myeloma. These diseases can be reduced with an early diagnosis which can be achieved using hemato oncology testing. For instance, in September 2025, according to Cancer Research UK, a UK-based charity, From 2024 to 2026, the incidence rate of leukemia in the UK is estimated at approximately 17.9 cases per 100,000 people per year, and it is projected to decrease by 3% to around 17.4 per 100,000 by 2038 to 2040. Therefore, the increasing incidence of hematologic cancer is driving the growth of the hemato-oncology testing market.
Which Segment Categories Are Influencing The Growth Trajectory Of The Hemato Oncology Testing Market?
The hemato oncology testing market covered in this report is segmented –
1) By Product And Services: Assay Kits And Reagents, Services
2) By Cancer Type: Leukemia, Lymphoma, Multiple Myeloma
3) By Technology: Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Next-Generation Sequencing (NGS)
4) By End User: Hospitals, Academic And Research Institutes
Subsegments:
1) By Assay Kits And Reagents: PCR Kits, Next-Generation Sequencing (NGS) Kits, Flow Cytometry Reagents, Antibodies
2) By Services: Testing Services, Data Analysis Services
Which Trends Are Reshaping Growth Within The Hemato Oncology Testing Market?
Major companies operating in the hemato-oncology testing market are introducing new innovations such as next-generation sequencing (NGS) to improve the accuracy and speed of genetic analysis, enable comprehensive profiling of hematologic malignancies, and facilitate personalized treatment strategies tailored to individual patient needs. Next-generation sequencing (NGS) is a high-throughput DNA sequencing technology that allows for the rapid and cost-effective analysis of entire genomes or targeted regions of DNA. For instance, in October 2024, NeoGenomics Inc., a US-based cancer diagnostics and genomic testing company launched AML Express, a next-generation sequencing (NGS) tool designed for the rapid detection of mutations associated with Acute Myeloid Leukemia (AML). This advanced diagnostic platform offers high accuracy and quick turnaround, supporting oncologists in making timely, targeted treatment decisions. AML Express aims to improve patient outcomes by providing precise mutation insights tailored to AML-specific genetic profiles.
Which Organizations Are Considered Principal Leaders In The Hemato Oncology Testing Market?
Major companies operating in the hemato oncology testing market are F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermo Fisher Scientific Inc., Illumina Inc., Invivoscribe Inc., Qiagen N.V., Bio-Rad Laboratories Inc., Archerdx Inc., ARUP Laboratories Inc., Asuragen Inc., Adaptive Biotechnologies Corp., Cepheid Inc., EntroGen Inc., CORE Diagnostics Inc., Genoptix Inc., GenPath Diagnostics, NeoGenomics Laboratories Inc., Siemens AG, Sysmex Corporation, Laboratory Corporation of America Holdings, Agilent Technologies, Danaher Corporation, Grifols SA, Diaorin SpA, HTG Molecular Diagnostics Inc., Admera Health
Get Your In-Depth Hemato Oncology Testing Market Report Now:
Which Regions Are Generating The Highest Demand Within The Hemato Oncology Testing Market?
North America was the largest region in the hemato oncology testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global hemato oncology testing market report during the forecast period. The regions covered in the hemato oncology testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: Market Research Reports
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: The Business Research Company | LinkedIn
Comments
Post a Comment